Lisavanbulin - Basilea Pharmaceutica

Drug Profile

Lisavanbulin - Basilea Pharmaceutica

Alternative Names: BAL-101553; BAL-27862

Latest Information Update: 25 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Basilea Pharmaceutica; The Adult Brain Tumor Consortium
  • Class Antineoplastics; Imidazoles; Oxadiazoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Glioblastoma
  • Preclinical Brain cancer
  • No development reported Breast cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Jun 2018 Efficacy, safety and pharmacokinetic data from a phase I/IIa trial in Soild tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology
  • 05 Jun 2018 Efficacy, safety and pharmacokinetics data from two phase I/IIa trials in Solid tumours released by Basilea Pharmaceutica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top